Safety and immunogenicity of inactivated poliovirus vaccine when
- Slides: 4
Safety and immunogenicity of inactivated poliovirus vaccine when given with measles– rubella combined vaccine and yellow fever vaccine and when given via different administration routes: a phase 4, randomised, non-inferiority trial in The Gambia Dr Ed Clarke, MBCh. B, Yauba Saidu, MD, Jane U Adetifa, MD, Ikechukwu Adigweme, MBBS, Mariama Badjie Hydara, MBBS, Adedapo O Bashorun, MBBS, Ngozi Moneke-Anyanwoke, MBBS, Ama Umesi, MBBS, Elishia Roberts, BSc, Pa Modou Cham, BSc, Michael E Okoye, MBBS, Kevin E Brown, MBBS, Prof Matthias Niedrig, Ph. D, Panchali Roy Chowdhury, MSc, Ralf Clemens, MD, Ananda S Bandyopadhyay, MBBS, Jenny Mueller, MD, David J Jeffries, Ph. D, Prof Beate Kampmann, MD The Lancet Global Health Volume 4 Issue 8 Pages e 534 -e 547 (August 2016) DOI: 10. 1016/S 2214 -109 X(16)30075 -4 Copyright © 2016 Clarke et al. Open Access article distributed under the terms of CC BY Terms and Conditions
Figure 1 The Lancet Global Health 2016 4 e 534 -e 547 DOI: (10. 1016/S 2214 -109 X(16)30075 -4) Copyright © 2016 Clarke et al. Open Access article distributed under the terms of CC BY Terms and Conditions
Figure 2 The Lancet Global Health 2016 4 e 534 -e 547 DOI: (10. 1016/S 2214 -109 X(16)30075 -4) Copyright © 2016 Clarke et al. Open Access article distributed under the terms of CC BY Terms and Conditions
Figure 3 The Lancet Global Health 2016 4 e 534 -e 547 DOI: (10. 1016/S 2214 -109 X(16)30075 -4) Copyright © 2016 Clarke et al. Open Access article distributed under the terms of CC BY Terms and Conditions
